Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Treatment strategies for high-risk MM

Jesús San Miguel • 7 May 2020
COMy Virtual 2020
Multiple Myeloma Alnuctamab Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Isatuximab Lenalidomide Melphalan

Jesus San Miguel, MD, Universidad de Navarra, Navarra, discusses treatment strategies for high-risk multiple myeloma patients, including immunotherapeutic options, such as monoclonal antibodies, bispecific antibodies and CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús San Miguel

PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials
4:12
PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials
Jesús San Miguel • 9 Sep 2025
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM
4:56
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM
Jesús San Miguel • 9 Sep 2025
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges
2:04
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges
Jesús San Miguel • 19 Sep 2024
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma?
1:28
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma?
Jesús San Miguel • 19 Sep 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Jesús San Miguel • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Jesús San Miguel • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Jesús San Miguel • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Jesús San Miguel • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals